Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
69 hedge funds and large institutions have $211M invested in Oyster Point Pharma, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 8 closing their positions.
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
19% more funds holding
Funds holding: 58 → 69 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
34% less capital invested
Capital invested by funds: $318M → $211M (-$108M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $207K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.28M |
| 2 |
Renaissance Technologies
New York
|
+$1.64M |
| 3 |
Morgan Stanley
New York
|
+$1.33M |
| 4 |
First Manhattan
New York
|
+$1.07M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
+$967K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.4M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$807K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$393K |
| 4 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$268K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$180K |
OYST Hedge Fund Activity: Q3 2021 in Review
69 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q3 2021, worth a combined $211M — down 34% from $318M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new OYST positions and 8 closed out — a net gain of 11 holders — while 16 added to existing stakes and 16 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $7.28M. The largest seller was Wellington Management Group, cutting an estimated $26.4M.
- 69 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q3 2021, up from 58 in Q2 2021.
- Funds reported $211M of Oyster Point Pharma, Inc. Common Stock stock for Q3 2021, down 34% quarter-over-quarter.
- 19 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q3 2021 and 8 closed out, a net change of +11 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q3 2021 was Point72 Asset Management, an estimated $7.28M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q3 2021 was Wellington Management Group, an estimated $26.4M sold.
Based on aggregated 13F filings for Q3 2021.